Chronic liver disease and hepatitis-B antigen: a prospective study

Area of Science:

• Hepatology
• Virology
• Immunology

Background:

• Chronic hepatitis and cirrhosis are significant liver conditions.
• Hepatitis-B antigen (HBAg) is a key marker in Hepatitis B virus infections.
• Understanding the clinical significance of HBAg in chronic liver disease is crucial.

Purpose of the Study:

• To investigate the long-term clinical course of patients with chronic hepatitis and cirrhosis.
• To determine if the presence of Hepatitis-B antigen (HBAg) defines a distinct clinical entity.
• To explore the relationship between HBAg, autoantibodies, and disease progression.

Main Methods:

• Long-term follow-up of 45 patients with chronic hepatitis and 41 with cirrhosis.
• Assessment of clinical, biochemical, and histological findings.
• Testing for the presence of Hepatitis-B antigen (HBAg) and autoantibodies.

Main Results:

• HBAg was detected in 42% of chronic hepatitis patients and 49% of cirrhosis patients.
• Clinical, biochemical, and histological findings were similar between HBAg-positive and HBAg-negative groups.
• Antigen persistence was observed for months to years; antigen disappearance correlated with potential disease resolution in the absence of irreversible lesions.

Conclusions:

• Hepatitis-B antigen-positive chronic liver disease does not appear to be a distinct clinical entity.
• The presence of HBAg and autoantibodies are not mutually exclusive.
• Disappearance of HBAg may indicate favorable prognosis for liver disease resolution if irreversible damage has not occurred.